Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Teva Strengthens Respiratory Franchise

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Company has entered into a definitive agreement to acquire MicroDose Therapeutx.

Teva Pharmaceutical Industries Ltd. has announced that it has entered into a definitive agreement to acquire MicroDose Therapeutx, a privately-held pharmaceutical and drug delivery company focused on inhalation technologies and products for lung diseases and infections with the potential to dramatically improve efficacy and patient compliance.

With the addition of MicroDose’s technologies and products, Teva is taking a significant step toward expanding its respiratory pipeline.

Teva will now have access to MicroDose’s proprietary technology including its multi-dose dry powder nebulizer device, which requires no preparation and can be administered in under 30 seconds.

MicroDose’s current pipeline is anchored by MDT-637 for respiratory syncytial virus (RSV) - an inhaled, low dose, small molecule, fusion inhibitor which prevents viral replication, delivered via MicroDose’s technology.

“I am thrilled that Teva can now count the exciting MicroDose products and technologies amongst our growing respiratory portfolio. The MicroDose platform is both simple and attractive, and their addition will help us to address the unmet needs of the youngest and oldest patients, who have a requirement for a better way of taking the medicines they rely upon,” stated Michael Hayden, President, Teva Global R&D, and Chief Scientific Officer.

Under the terms of the deal, Teva will acquire all of MicroDose’s outstanding shares for a payment at closing of $40 million, additional payments of up to $125 million upon achievement of regulatory and development milestones, plus sales-based milestones and tiered royalty payments upon commercialization of MDT-637 and an earlier stage Asthma/COPD medicine.

Anand V. Gumaste, President, CEO and Chairman of MicroDose, stated, “We believe this agreement provides a unique opportunity to advance MicroDose’s platform technology and development programs for the greatest benefit of patients. Teva has a strong and growing franchise in respiratory diseases, with extensive experience in both delivery mechanisms and novel therapeutic modalities. Teva also has a worldwide market presence and leading global supply chain.”

Stifel acted as exclusive financial advisor to MicroDose Therapeutx in this transaction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Teva, AbCellera Launch Collaboration
Agreement further supports Teva’s novel biologics development program.
Wednesday, February 03, 2016
Teva, Takeda Collaborate
Teva Pharmaceutical Industries and Takeda Pharmaceutical Company Limited have announced that the two companies have entered into a definitive agreement to establish an unprecedented partnership in Japan.
Wednesday, December 02, 2015
Teva Acquires Rimsa
Strategic move enhances Teva’s presence in Mexico, the second largest market in Latin America and a major emerging market.
Friday, October 09, 2015
Teva to Acquire Gecko Health Innovations
Teva Pharmaceutical Industries Ltd., and Gecko Health Innovations, Inc have announced that they have entered into a definitive agreement in which Teva will acquire Gecko Health Innovations.
Thursday, October 01, 2015
Teva Announces FDA Acceptance of NDA for SD-809 for Huntington Disease Treatment
The FDA designates orphan status to drugs and biologics that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S.
Monday, August 17, 2015
Teva and Microchips Biotech Announce Partnership
Promising innovative technology offers potential across therapeutic areas and disease states.
Thursday, June 25, 2015
Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
All-cash transaction with enterprise value of $3.2 billion.
Thursday, April 02, 2015
Teva to Acquire Labrys Biologics, Inc.
Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise.
Thursday, June 05, 2014
Teva Expands CNS Specialty Business with Acquisition of NuPathe
Teva will acquire NuPathe Inc. for $3.65 per share in cash.
Tuesday, January 28, 2014
Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture
Teva to pursue its biologics strategy to create a balanced portfolio of biosimilars, biobetters and innovative biologics.
Friday, July 26, 2013
Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia in Breast Cancer Patients Undergoing Chemotherapy
Clinical results for Lipegfilgrastim and Balugrastim highlighted at oncology conference.
Tuesday, July 03, 2012
Teva Sees Limited Competition in Biosimilar Market
The company expects the fledgling market for so-called biosimilar drugs to be big, but the cost and complexity of developing them will limit competition, company executives said.
Monday, January 16, 2012
Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe
Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis.
Friday, December 23, 2011
Teva Announces Drug Development Investment in Cocrystal Discovery Inc.
Cocrystal Discovery Inc. will initially develop an antiviral drug targeting the polymerase enzyme of the Hepatitis C virus for Teva.
Friday, September 23, 2011
Teva Announce the Completion of Enrollment in Laquinimod Phase III Clinical Trial
Teva and Active Biotech to commence the Allegro study to evaluate the oral investigational compound in relapsing-remitting multiple sclerosis.
Thursday, November 20, 2008
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!